FOXM1 and breast carcinoma: Our study utilizing pharmacophore-based virtual screening and molecular docking analysis identified for the first time that two FDA-approved anti-acid drugs, Pantoprazole and Rabeprazole, as potential FOXM1 inhibitors and that these drugs may be used in cancer therapy for targeting FOXM1-driven cancers, including breast cancer.